James Rolke
Amministratore Delegato presso REVELATION BIOSCIENCES, INC.
Patrimonio netto: 1 451 $ in data 30/04/2024
Posizioni attive di James Rolke
Società | Posizione | Inizio | Fine |
---|---|---|---|
REVELATION BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/05/2020 | - |
Amministratore Delegato | 01/05/2020 | - | |
Revelation Therapeutics LLC
Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | Direttore/Membro del Consiglio | - | - |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Direttore/Membro del Consiglio | 01/05/2020 | - |
Amministratore Delegato | 01/05/2020 | - |
Storia della carriera di James Rolke
Precedenti posizioni note di James Rolke
Società | Posizione | Inizio | Fine |
---|---|---|---|
LA JOLLA PHARMACEUTICAL COMPANY | Direttore Tecnico/Scientifico/R&S | 01/02/2012 | 31/05/2020 |
Pluromed, Inc.
Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | Direttore Tecnico/Scientifico/R&S | 01/07/2009 | 01/01/2012 |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Corporate Officer/Principal | 01/01/2007 | 01/01/2009 |
MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2006 | 01/01/2007 |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2003 | 01/01/2006 |
Geltex, Inc. | Corporate Officer/Principal | - | - |
░░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formazione di James Rolke
Keene State College | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 13 |
Posizioni
Corporate Officer/Principal | 6 |
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Settori
Health Technology | 7 |
Commercial Services | 3 |
Electronic Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MERSANA THERAPEUTICS, INC. | Health Technology |
REVELATION BIOSCIENCES, INC. | Health Technology |
Aziende private | 9 |
---|---|
Alpha-Beta Technology, Inc.
Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Technology |
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
Pluromed, Inc.
Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | Health Technology |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Health Technology |
Surgical Sealants, Inc. | |
Revelation Therapeutics LLC
Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | Commercial Services |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Health Technology |
Geltex, Inc. |
- Borsa valori
- Insiders
- James Rolke
- Esperienza